Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Petra J. Woestenberg; Audrey J. King; Birgit H.B. Van Benthem; Suzan Leussink; Marianne A.B. Van Der Sande; Christian J.P.A. Hoebe; Johannes A. Bogaards

doi:10.1093/infdis/jiz187

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Petra J. Woestenberg^*, Audrey J. King, Birgit H.B. Van Benthem, Suzan Leussink, Marianne A.B. Van Der Sande, Christian J.P.A. Hoebe, Johannes A. Bogaards

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Original language	English
Pages (from-to)	1280-1285
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	221
Issue number	8
DOIs	https://doi.org/10.1093/infdis/jiz187
Publication status	Published - 2020

Access to Document

10.1093/infdis/jiz187

Cite this

Woestenberg, P. J., King, A. J., Van Benthem, B. H. B., Leussink, S., Van Der Sande, M. A. B., Hoebe, C. J. P. A., & Bogaards, J. A. (2020). Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands. Journal of Infectious Diseases, 221(8), 1280-1285. https://doi.org/10.1093/infdis/jiz187

@article{8cdbee2169c444bba620b37edc6d7d26,

title = "Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands",

abstract = "Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.",

keywords = "Anal cancer, Human papillomavirus (HPV), Human papillomavirus vaccine, Public health, Vaccine effectiveness",

author = "Woestenberg, {Petra J.} and King, {Audrey J.} and {Van Benthem}, {Birgit H.B.} and Suzan Leussink and {Van Der Sande}, {Marianne A.B.} and Hoebe, {Christian J.P.A.} and Bogaards, {Johannes A.}",

year = "2020",

doi = "10.1093/infdis/jiz187",

language = "English",

volume = "221",

pages = "1280--1285",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "8",

}

Woestenberg, PJ, King, AJ, Van Benthem, BHB, Leussink, S, Van Der Sande, MAB, Hoebe, CJPA & Bogaards, JA 2020, 'Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands', Journal of Infectious Diseases, vol. 221, no. 8, pp. 1280-1285. https://doi.org/10.1093/infdis/jiz187

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands. / Woestenberg, Petra J.; King, Audrey J.; Van Benthem, Birgit H.B. et al.

In: Journal of Infectious Diseases, Vol. 221, No. 8, 2020, p. 1280-1285.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

AU - Woestenberg, Petra J.

AU - King, Audrey J.

AU - Van Benthem, Birgit H.B.

AU - Leussink, Suzan

AU - Van Der Sande, Marianne A.B.

AU - Hoebe, Christian J.P.A.

AU - Bogaards, Johannes A.

PY - 2020

Y1 - 2020

N2 - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

AB - Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

KW - Anal cancer

KW - Human papillomavirus (HPV)

KW - Human papillomavirus vaccine

KW - Public health

KW - Vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85074989345&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz187

DO - 10.1093/infdis/jiz187

M3 - Article

C2 - 31100134

AN - SCOPUS:85074989345

VL - 221

SP - 1280

EP - 1285

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Abstract

Access to Document

Other files and links

Cite this